Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical
trials. Success has been reported in non–small and small cell lung carcinomas and …

Cyclin-dependent kinases (CDKs) are proteins pivotal to a wide range of cellular functions,
most importantly cell division and transcription, and their dysregulations have been …

Introduction Breast cancer remains a significant scientific, clinical and societal challenge.
This gap analysis has reviewed and critically assessed enduring issues and new challenges …

While cancer is commonly described as “a disease of the genes”, it is also a disease of
metabolism. Indeed, carcinogenesis and malignancy are highly associated with metabolic re …

Objective To harmonize standard operating procedures (SOPs) and standardize the
recording of associated data for collection, processing, and storage of human tissues …

Background: Triple negative breast carcinomas (TNBC) do not benefit from hormonal or
Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in …

A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare
pathogenic mutations, often based on evidence from patients having dissimilar but more …

Over the last decade genomics and other molecular biosciences have enabled new
capabilities that, according to many, have the potential to revolutionize medicine and …

In this review, we will discuss how the cell of origin may modulate breast cancer intratumoral
heterogeneity (ITH) as well as the role of ITH in the evolution of cancer. The clonal evolution …

The largest subtype of breast cancer is characterized by the expression and activity of the
estrogen receptor alpha (ERalpha/ER). Although several effective therapies have …